Clinical Trial

HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 1b, open-label, multi-center study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of HS-20093 in patients with advanced gastric and gastroesophageal junction adenocarcinoma.
Trial Details
NCT Number NCT07462923
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Enrollment 40 participants
Start Date 2026-01-29
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-10